Antitumor activity of recombinant-derived interferon alpha in XXXX .

@entity1 @entity1358 @entity137
Fifty-six @entity1 with @entity1358 ( @entity1358 ) were treated with recombinant DNA-derived interferon alpha (rIFN alpha A). The first 30 @entity1 were randomized between doses of 2 X 10(6) U/m2 and 20 X 10(6) U/m2 intramuscularly daily. No complete (CR) or partial (PR) remissions were achieved in 15 @entity1 receiving the low dose. In contrast, 27% of those receiving the high dose achieved CR or PR. Subsequently, 26 additional @entity1 were given the high dose and achieved a 31% response rate. Remissions lasted from 1 to more than 12 months (median, 3 months). Responses occurred predominantly in lung parenchyma or mediastinal node metastases. @entity137 of the high dose required dose reduction in 50% of the patients. Neutralizing antibodies to rIFN alpha A developed in seven of 12 responsive (58%) and nine of 29 (31%) nonresponsive @entity1 (P = greater than .5). The median duration of remission among the antibody-positive and antibody-negative @entity1 were 2 and 10 months, respectively (P = .009). The clinical significance of the antibodies to rIFN alpha A remains unclear, but the coincidence between the detection of antibodies and the early relapse of the disease in some responsive @entity1 suggests that these antibodies may abrogate the biologic activity of rIFN alpha A. This effect, however, was not associated with adverse clinical sequelae.
